BD Announces First Fiscal Quarter Results; Raises Fiscal 2021 Guidance
- First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%.
- BD s COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis. This includes BD Veritor™ Plus System revenues of $688 million.
- First fiscal quarter GAAP diluted earnings per share (EPS) increased 285% year-over-year to $3.35.
- Adjusted EPS increased 71.7% year-over-year to $4.55.
- BD is updating its fiscal 2021 guidance, including raising its fiscal 2021 adjusted EPS guidance to $12.75-$12.85.
News provided by
Share this article
Share this article
FRANKLIN LAKES, N.J., Feb. 4, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31, 2020. This represents
Share this article
Share this article
FRANKLIN LAKES, N.J., Feb. 2, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs).
The results of the CLEAN3 trial
The Lancet Infectious Diseases, showed the use of the BD vascular care solution resulted in fewer PIVC failures compared with the standard group (34.8% vs. 47.5%, respectively) and extended the median time between catheter insertion and failure (50.4 hours vs 30.0 hours, respectively). PIVC failure was defined as any premature removal of PIVC before end of treatment – other than for routine replacement – and included phlebitis, infiltration, occlusion, dislodgment, local infection and catheter-related bloodstream infection (whichever occurred first).
(2)
- There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes
- Compared with standard approaches, the BD vascular care solution reduced the relative risk of catheter failure by 27%, resulting in longer catheter dwell time without complications
- The use of 2% CHG 70% IPA single use, sterile applicator skin antiseptic reduced the risk of infectious complications (catheter colonization and local infection) by 92% compared with 5% povidone iodine (PVI) 69% ethanol
FRANKLIN LAKES, N.J., Feb. 2, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs).
Eitan Medical Receives FDA Clearance for Upgraded Sapphire™ Infusion Pump System
USA - English
News provided by
Share this article
Share this article
NETANYA, Israel, Jan. 19, 2021 /PRNewswire/ Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions across the care continuum, announced today that its upgraded Sapphire™ infusion pump system software Rev15, which includes the infusion pump, administration sets and accessories, has received US Food and Drug Administration (FDA) 510(k) clearance. The Sapphire™ infusion system is the company s flagship infusion device, and is used across the U.S. within alternate sites, homecare markets, emergency medical services (EMS) and hospitals.
FRANKLIN LAKES, N.J., Jan. 12, 2021 /PRNewswire/ BD , a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal. | January 16, 2021